tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2017-95-6-22-29tiblj-1009Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESСПЕКТР И ФАКТОРЫ РИСКА НЕЖЕЛАТЕЛЬНЫХ ПОБОЧНЫХ РЕАКЦИЙ ПРИ ЛЕЧЕНИИ ВПЕРВЫЕ ВЫЯВЛЕННЫХ БОЛЬНЫХ ТУБЕРКУЛЕЗОМPROFILE AND RISK FACTORS OF ADVERSE REACTIONS IN NEW TUBERCULOSIS CASES RECEIVING TREATMENTИвановаД. А.IvаnovаD. A.

Иванова Диана Александровна - кандидат медицинских наук, ведущий научный сотрудник научно-клинического отдела.

107014, Москва, ул. Стромынка, д. 10, тел./факс: 8 (499) 269-14-10, 8 (495) 964-86-37

Diana A. Ivanova - Candidate of Medical Sciences, Leading Researcher of Research Clinical Department.

10, Stronymka St., Moscow, 107014,Phone/Fax: +7 (499) 269-14-10; +7 (495) 964-86-37

d-ivanova@list.ruБорисовС. Е.BorisovS. E.

Борисов  Сергей Евгеньевич - заместитель директора по научно-клинической работе.

107014, Москва, ул. Стромынка, д. 10, тел./факс: 8 (499) 268-00-05, 8 (495) 964-86-37

Sergey E. Borisov - Deputy Director for Research and Clinical Activities.

10, Stronymka St., Moscow, 107014, Phone/Fax: 8 (499) 268-00-05, 8 (495) 964-86-37

sebarsik@gmail.comГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»РоссияMoscow Municipal Scientific - Practical Center of Tuberculosis Control, Health Department of MoscowRussian Federation2017050720179562229Copyright © Иванова Д.А., Борисов С.Е., 20172017Иванова Д.А., Борисов С.Е.Ivаnovа D.A., Borisov S.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1009

С целью оценки частоты и факторов  риска нежелательных побочных реакций проанализированы результаты  мониторинга  клинико-лабораторных показателей 435 впервые выявленных больных туберкулезом  органов дыхания в ходе интенсивной  фазы противотуберкулезной химиотерапии. Нежелательные побочные реакции развились у 95,2% больных (95%-ный ДИ 92,7-96,9); тяжелые реакции – у 48,7% больных; коррекция схемы терапии потребовалась в 72,7% случаев. В спектре побочных реакций лидировали гепатотоксические (59,3%), аллергические (53,6%), гастроинтестинальные (35,6%), гиперурикемия (61,6%). Для каждого из указанных типов побочных реакций выявлен набор факторов риска, позволяющий прогнозировать и предупреждать их развитие до начала химиотерапии.

In order to evaluate  the frequency  and risk factors of adverse reactions,  the monitoring results  of clinical and laboratory tests  of 435 new cases of respiratory tuberculosis being on the intensive phase of chemotherapy have been analyzed. 95.2% of patients had adverse reactions (95% CI 92.7-96.9); 48.7% demonstrated severe adverse reactions and in 72.7% treatment regimen had to be changed. Regarding the profile of adverse reactions, hepatotoxic ones prevailed (59.3%), they were followed by allergic reactions  (53.6%), gastrointestinal reactions  (35.6%) and hyperuricemia (61.6%). Certain risk factors have been identified for each of the above types of adverse reactions, making it possible to predict and prevent them prior to the start of chemotherapy.

нежелательные побочные реакциифакторы рискагепатотоксичностьлекарственная аллергиягастроинтестинальные реакциигиперурикемияReferencesАстахова А. В., Лепахин В. К. Лекарства: неблагоприятные побочные эффекты и контроль безопасности. 2-е изд. – М.: ЭКСМО, 2008.Аstakhova А.V., Lepakhin V.K. Lekarstva: neblagopriyantye pobochnye effekty i kontrol bezopasnosti. [Drugs: adverse reactions and safety control]. 2nd ed., Moscow, EKSMO Publ., 2008.Мишин В. Ю. Медикаментозные осложнения комбинированной химиотерапии туберкулеза легких. – М.: ООО «Медицинское информационное агентство», 2007. – 248 с.Mishin M.Yu, Medikamentoznye oslozhneniya kombinirovannoy khimioterapii tuberkuleza legkikh. [Drug-associated complication of combined chemotherapy of pulmonary tuberculosis]. Moscow, OOO Meditsinskoye informatsionnoye agentstvo Publ., 2007, 248 p.Мордык А. В., Кондря А. В., Гапоненко Г. Е. Частота неблагоприятных побочных реакций на противотуберкулезные препараты у впервые выявленных больных туберкулезом органов дыхания старше 18 лет, и факторы, влияющие на их развитие // Туб. и болезни легких. – 2010. – № 2. – С. 44-48.Mordyk А.V., Kondrya А.V., Gaponenko G.E. Frequency of adverse reactions to tuberculosis drugs in new respiratory tuberculosis patients older than 18 years and factors influencing on their development. Tuberculosis and Lung Diseases, 2010, no. 2, pp. 44-48. (In Russ.)Туберкулез в Российской Федерации, 2012/2013/2014 гг.: аналитический обзор основных статистических показателей по туберкулезу, используемых в Российской Федерации и в мире. – М., 2015. – 312 с.Tuberkulez v Rossiyskoy Federatsii 2012, 2013, 2014 g. Аnaliticheskiy obzor statisticheskikh pokazateley, ispolzuemykh v Rossiyskoy Federatsii i v mire. [Tuberculosis in the Russian Federation in 2011, 2013. 2014. Analytic review of statistic rates used in the Russian Federation and in the world]. Moscow, 2015, 312 p.Beydoun M. A., Canas J. A., Beydoun H. A. et al. Serum antioxidant concentrations and metabolic syndrome are associated among U.S. adolescents in recent national surveys // J. Nutr. – 2012. – Vol. 142, № 9. – P. 1693-1704.Beydoun M.A., Canas J.A., Beydoun H.A. et al. Serum antioxidant concentrations and metabolic syndrome are associated among U.S. adolescents in recent national surveys. J. Nutr., 2012, vol. 142, no. 9, pp. 1693-1704.Bidell M. R., Lodise T. P. Fluoroquinolone-associated tendinopathy: does levofloxacin pose the greatest risk? // Pharmacotherapy. – 2016. – Vol. 36, № 6. – P. 679-693.Bidell M.R., Lodise T.P. Fluoroquinolone-associated tendinopathy: does levofloxacin pose the greatest risk? Pharmacotherapy, 2016, vol. 36, no. 6, pp. 679-693.Division of Microbiology and Infection Diseases (DMID) adult toxicity table. National Institute of Allergy and Infectious Diseases, Bethesda, 2007. URL: http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/Documents/dmidadulttox.pdf (дата обращения: 09.07.2013)Division of Microbiology and Infection Diseases (DMID) adult toxicity table. National Institute of Allergy and Infectious Diseases, Bethesda, 2007. URL: http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/Documents/dmidadulttox.pdf (Accesses as of 09.07.2013)Ford E. S., Choi H. K. Associations between concentrations of uric acid with concentrations of vitamin A and beta-carotene among adults in the United States // Nutr. Res. – 2013. – Vol. 33. – №12. – P. 995-1002.Ford E.S., Choi H.K. Associations between concentrations of uric acid with concentrations of vitamin A and beta-carotene among adults in the United States. Nutr. Res., 2013, vol. 33, no. 12, pp. 995-1002.Javadi M. R., Shalviri G., Gholami K. et al. Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors // Pharmacoepidemiol Drug Saf. – 2007. – Vol. 16, № 10. – Р. 1104-1110.Javadi M.R., Shalviri G., Gholami K. et al. Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors. Pharmacoepidemiol Drug Saf., 2007, vol. 16, no. 10, pp. 1104-1110.Kumar A. K., Gurumurthy P. Disposition of uric acid upon administration of ofloxacin alone and in combination with other anti-tuberculosis drugs // Indian. J. Exp. Biol. – 2004. – Vol. 42, № 3. – P. 323-325.Kumar A.K., Gurumurthy P. Disposition of uric acid upon administration of ofloxacin alone and in combination with other anti-tuberculosis drugs. Indian. J. Exp. Biol., 2004, vol. 42, no. 3, pp. 323-325.Nagayama N., Masuda K., Baba M. et al. Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin // Kekkaku. – 2003. – Vol. 78, № 4. – Р. 339-346.Nagayama N., Masuda K., Baba M. et al. Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin. Kekkaku, 2003, vol. 78, no. 4, pp. 339-346.Preventing and minimizing risks associated with antituberculosis medicines to improve patient safety. Management Sciences for Health, Arlington, 2013. URL: http://siapsprogram.org/wp-content/uploads/2014/02/14-033-Min-RiskAnti-TB-Meds-final.pdf. (дата обращения: 18.10.2016)Preventing and minimizing risks associated with antituberculosis medicines to improve patient safety. Management Sciences for Health, Arlington, 2013. URL: http://siapsprogram.org/wp-content/uploads/2014/02/14-033-Min-RiskAnti-TB-Meds-final.pdf. (Accessed as of 18.10.2016)Ramappa V., Aithal G. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management // J. Clin. and Experimental Hepatology. – 2012. – Vol 3, № 1. – Р. 37-49.Ramappa V., Aithal G. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J. Clin. and Experimental Hepatology, 2012, vol. 3, no. 1, pp. 37-49.Saukkonen J. J., Cohn D. L., Jasmer R. M. еt al. An official ATS Statement: hepatotoxicity of antituberculosis therapy // Am. J. Respir. Crit. Care Med. – 2006. – Vol. 174, № 8. – Р. 935-952.Saukkonen J.J., Cohn D.L., Jasmer R.M. еt al. An official ATS Statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med., 2006, vol. 174, no. 8, pp. 935-952.Shakya R., Rao B., Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors // Ann. Pharmacother. – 2004. – Vol. 38, № 6. – P. 1074-1079.Shakya R., Rao B., Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann. Pharmacother., 2004, vol. 38, no. 6, pp. 1074-1079.Singla R., Sharma S. K., Mohan A. et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity // Indian J. Med. Res. – 2010. – Vol. 132. – P. 81-86.Singla R., Sharma S.K., Mohan A. et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J. Med. Res., 2010, vol. 132, pp. 81-86.Vieira D. E., Gomes M. Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil // J. Bras. Pneumol. – 2008. – Vol. 34. – № 12. – Р. 1049-1055.Vieira D.E., Gomes M. Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil. J. Bras. Pneumol., 2008, vol. 34, no. 12, pp. 1049-1055.Zaverucha-do-Valle C., Monteiro S. P., El-Jaick K. B. et al. The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients // Tuberculosis (Edinb). – 2014. – Vol. 94, № 3. – P. 299-305.Zaverucha-do-Valle C., Monteiro S.P., El-Jaick K.B. et al. The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients. Tuberculosis (Edinb.), 2014, vol. 94, no. 3, pp. 299-305.

The authors declare that there are no conflicts of interest present.